Table 3.

Variants associated with the survival of breast cancer patients in the meta-analysis of BRCA1 and BRCA2 carriers.

Variant	Chr:position	Effect allele	Reference allele	EAF	Analysis group	Genetic model	BRCA1 HR [95% CI]	BRCA2 HR [95% CI]	Meta-analysis HR [95% CI]	P.LR	BFDP (1.3)	BFDP (1.8)	BFDP (2.5)
rs551383190	1:91487202	C	A	0.14	BRCA1/BRCA2	Per-allele linear	0.57 [0.45–0.74]	0.66 [0.50–0.88]	0.61 [0.51–0.73]	7.0E−08	0.46	0.05	0.04
rs117422049	2:122474495	A	G	0.011	BRCA1/BRCA2	Per-allele linear	2.67 [1.74–4.10]	3.05 [1.80–5.17]	2.80 [1.89–4.13]	2.6E−07	0.99	0.64	0.25
rs4879914	9:35621336	C	T	0.55	BRCA1/BRCA2	Per-allele linear	1.26 [1.11–1.43]	1.36 [1.16–1.59]	1.30 [1.17–1.44]	4.7E−07	0.31	0.21	0.25
rs2320070	14:22380540	T	C	0.74	BRCA1/BRCA2	Per-allele linear	1.42 [1.19–1.68]	1.35 [1.10–1.65]	1.39 [1.22–1.58]	4.6E−07	0.44	0.20	0.22

Chr chromosome, EAF effect allele frequency in data, HR hazard ratio, CI confidence interval, P.LR P-value from likelihood-ratio test, BFDP Bayesian false discovery probability.